Sign In
Buy PSNL
$10.78
-0.360 (-3.23%)
At Close: Jun 03, 2026
Personalis, Inc. $PSNL Shares Acquired by Aberdeen Group plc
03:06am, Monday, 06'th Apr 2026
Aberdeen Group plc lifted its holdings in shares of Personalis, Inc. (NASDAQ: PSNL) by 36.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities
Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Recommendation of “Moderate Buy” from Analysts
02:17am, Sunday, 05'th Apr 2026
Shares of Personalis, Inc. (NASDAQ: PSNL - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the company, Marketbeat.c
Personalis to Participate in the 25th Annual Needham Virtual Conference
04:01pm, Wednesday, 01'st Apr 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the 25th Annu
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption
04:00pm, Tuesday, 17'th Mar 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of P
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®
06:00am, Thursday, 12'th Mar 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clin
Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of “Moderate Buy” from Analysts
02:44am, Wednesday, 11'th Mar 2026
Personalis, Inc. (NASDAQ: PSNL - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight research firms that are currently covering the stock, Marketbeat Ratings repo
Personalis, Inc. (NASDAQ:PSNL) Sees Large Increase in Short Interest
02:14am, Friday, 06'th Mar 2026
Personalis, Inc. (NASDAQ: PSNL - Get Free Report) was the target of a large increase in short interest in February. As of February 13th, there was short interest totaling 10,685,978 shares, an increas
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
11:37pm, Thursday, 26'th Feb 2026
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates
06:31pm, Thursday, 26'th Feb 2026
Personalis (PSNL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.23 per share a year ago.
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
04:01pm, Thursday, 26'th Feb 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the fourth quarter and ful
Personalis (NASDAQ:PSNL) Shares Down 4.8% – Time to Sell?
04:36am, Sunday, 22'nd Feb 2026
Personalis, Inc. (NASDAQ: PSNL - Get Free Report)'s stock price was down 4.8% during mid-day trading on Friday. The stock traded as low as $8.38 and last traded at $8.4780. Approximately 194,504 share
Personalis (PSNL) to Release Earnings on Thursday
03:22am, Thursday, 19'th Feb 2026
Personalis (NASDAQ: PSNL - Get Free Report) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Personalis to post earnings of ($0.31) per s
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
04:01pm, Tuesday, 17'th Feb 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen 46th An
Personalis Gets Medicare Coverage For Lung Cancer Surveillance Test
09:18am, Tuesday, 10'th Feb 2026
Personalis (PSNL) stock up in premarket on Medicare coverage for its NeXT Personal test for lung cancer surveillance.
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
06:00am, Tuesday, 10'th Feb 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company's NeXT Personal molecular res
